JP2009539802A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539802A5
JP2009539802A5 JP2009513691A JP2009513691A JP2009539802A5 JP 2009539802 A5 JP2009539802 A5 JP 2009539802A5 JP 2009513691 A JP2009513691 A JP 2009513691A JP 2009513691 A JP2009513691 A JP 2009513691A JP 2009539802 A5 JP2009539802 A5 JP 2009539802A5
Authority
JP
Japan
Prior art keywords
weight
mass
pharmaceutical composition
mpa
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009513691A
Other languages
English (en)
Japanese (ja)
Other versions
JP4743321B2 (ja
JP2009539802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/055582 external-priority patent/WO2007141298A1/en
Publication of JP2009539802A publication Critical patent/JP2009539802A/ja
Publication of JP2009539802A5 publication Critical patent/JP2009539802A5/ja
Application granted granted Critical
Publication of JP4743321B2 publication Critical patent/JP4743321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009513691A 2006-06-09 2007-06-06 フェソテロジンを含む安定した医薬組成物 Active JP4743321B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011942.7 2006-06-09
EP06011943.5 2006-06-09
EP06011941 2006-06-09
EP06011941.9 2006-06-09
EP06011943 2006-06-09
PCT/EP2007/055582 WO2007141298A1 (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011041842A Division JP4781489B2 (ja) 2006-06-09 2011-02-28 フェソテロジンを含む安定した医薬組成物

Publications (3)

Publication Number Publication Date
JP2009539802A JP2009539802A (ja) 2009-11-19
JP2009539802A5 true JP2009539802A5 (cg-RX-API-DMAC7.html) 2011-05-06
JP4743321B2 JP4743321B2 (ja) 2011-08-10

Family

ID=38521333

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009513691A Active JP4743321B2 (ja) 2006-06-09 2007-06-06 フェソテロジンを含む安定した医薬組成物
JP2011041842A Active JP4781489B2 (ja) 2006-06-09 2011-02-28 フェソテロジンを含む安定した医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011041842A Active JP4781489B2 (ja) 2006-06-09 2011-02-28 フェソテロジンを含む安定した医薬組成物

Country Status (37)

Country Link
EP (1) EP2029134B1 (cg-RX-API-DMAC7.html)
JP (2) JP4743321B2 (cg-RX-API-DMAC7.html)
KR (1) KR101316773B1 (cg-RX-API-DMAC7.html)
CN (1) CN101466371B (cg-RX-API-DMAC7.html)
AP (1) AP2416A (cg-RX-API-DMAC7.html)
AR (1) AR061289A1 (cg-RX-API-DMAC7.html)
AT (1) ATE517619T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007255408B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712865B1 (cg-RX-API-DMAC7.html)
CA (1) CA2652712C (cg-RX-API-DMAC7.html)
CR (1) CR10494A (cg-RX-API-DMAC7.html)
CU (1) CU23850B1 (cg-RX-API-DMAC7.html)
CY (1) CY1111934T1 (cg-RX-API-DMAC7.html)
DK (1) DK2029134T3 (cg-RX-API-DMAC7.html)
EA (1) EA015909B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP089010A (cg-RX-API-DMAC7.html)
ES (1) ES2370943T3 (cg-RX-API-DMAC7.html)
GT (1) GT200800276A (cg-RX-API-DMAC7.html)
HR (1) HRP20110776T1 (cg-RX-API-DMAC7.html)
IL (2) IL195732A (cg-RX-API-DMAC7.html)
MA (1) MA30504B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008015736A (cg-RX-API-DMAC7.html)
MY (1) MY146574A (cg-RX-API-DMAC7.html)
NI (1) NI200800318A (cg-RX-API-DMAC7.html)
NL (1) NL2000690C2 (cg-RX-API-DMAC7.html)
NO (1) NO341980B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ572616A (cg-RX-API-DMAC7.html)
PE (2) PE20080331A1 (cg-RX-API-DMAC7.html)
PL (1) PL2029134T3 (cg-RX-API-DMAC7.html)
PT (1) PT2029134E (cg-RX-API-DMAC7.html)
RS (1) RS51973B (cg-RX-API-DMAC7.html)
SI (1) SI2029134T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN08505A1 (cg-RX-API-DMAC7.html)
TW (2) TWI520735B (cg-RX-API-DMAC7.html)
UY (1) UY30394A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007141298A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806411B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
KR20120014583A (ko) 2009-05-11 2012-02-17 라티오팜 게엠베하 타르타르산 염 형태의 데스페소테로딘
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2549985A1 (en) * 2010-03-22 2013-01-30 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
US20140199401A1 (en) * 2011-07-04 2014-07-17 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
KR20250154562A (ko) 2012-11-02 2025-10-28 머레이 앤 풀 엔터프라이지즈, 리미티드 콜히친 유도체의 투여를 통한 심혈관성 병태의 치료 또는 예방
EA037375B1 (ru) 2013-04-16 2021-03-22 Марри Энд Пул Энтерпрайзес Лимитед Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
DK2986280T3 (da) * 2013-04-16 2021-06-14 Murray & Poole Entpr Ltd Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (en) 2018-04-26 2019-10-31 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
CA3187827A1 (en) * 2020-06-30 2022-01-06 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine
JPWO2023145486A1 (cg-RX-API-DMAC7.html) * 2022-01-28 2023-08-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Similar Documents

Publication Publication Date Title
JP2009539802A5 (cg-RX-API-DMAC7.html)
HRP20110776T1 (hr) Stabilizirani farmaceutski sastavi koji sadrže fesoterodin
JP2016006108A5 (cg-RX-API-DMAC7.html)
RU2008148547A (ru) Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением
HRP20160454T1 (hr) Kombinacija spoja morfinana i antidepresiva za liječenje pseudobulbarnog afekta
JP2011515349A5 (cg-RX-API-DMAC7.html)
JP2010209104A5 (cg-RX-API-DMAC7.html)
JP2012236837A5 (cg-RX-API-DMAC7.html)
JP2016525572A5 (cg-RX-API-DMAC7.html)
HRP20170682T1 (hr) Kruti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksokinolin-3-karboksamida
JP2017537954A5 (cg-RX-API-DMAC7.html)
JP2011510024A5 (cg-RX-API-DMAC7.html)
JP2011503300A5 (cg-RX-API-DMAC7.html)
JP2010523492A5 (cg-RX-API-DMAC7.html)
JP2013535477A5 (cg-RX-API-DMAC7.html)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
CN104321056A (zh) 用于缓解尿频的延长释放制剂及其使用方法
JP2011513393A5 (cg-RX-API-DMAC7.html)
JP2013514979A5 (cg-RX-API-DMAC7.html)
JP2017502948A (ja) 新規な組成物
RU2018111690A (ru) Пероральная лекарственная форма будесонида
JPWO2021246388A5 (cg-RX-API-DMAC7.html)
HRP20171330T1 (hr) Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola
JP2013032308A5 (cg-RX-API-DMAC7.html)
JP2017507966A5 (cg-RX-API-DMAC7.html)